Loading...
Market
How many countries will start LSCD stem-cell treatment trials by end of 2025?
2
Resolution / Starting Odds
0 countries • 25%
1-2 countries • 25%
3-4 countries • 25%
5 or more countries • 25%
Clinical trial registries or official announcements from health ministries
Story
World-First Stem-Cell Treatment Restores Vision to 20/20 for Four Patients with Limbal Stem Cell Deficiency in Japan
Nov 8, 2024, 09:42 PM
A groundbreaking treatment using corneal epithelial cell sheets derived from human induced pluripotent stem cells (iPSCs) has restored vision in patients with limbal stem cell deficiency (LSCD). This world-first procedure was conducted in Japan as part of a single-arm, open-label, first-in-human interventional study. Four individuals with damaged corneas received the stem-cell transplants, and initial results indicate that the treatment is safe, although further testing in larger trials is necessary. Notably, one patient, previously legally blind, has achieved better than 20/20 vision following the procedure. The study highlights the potential of stem-cell therapies in restoring vision and addressing severe ocular conditions.
View original story
Similar markets
Japan • 25%
USA • 25%
EU • 25%
Other • 25%
1-2 countries • 25%
3-5 countries • 25%
6-10 countries • 25%
More than 10 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
0-4 • 25%
5-9 • 25%
10-14 • 25%
15 or more • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 20 countries • 25%
20 to 40 countries • 25%
41 to 60 countries • 25%
More than 60 countries • 25%
No countries • 25%
1 to 5 countries • 25%
6 to 10 countries • 25%
More than 10 countries • 25%
United States • 25%
Germany • 25%
Japan • 25%
Other • 25%
1-2 countries • 33%
3-4 countries • 33%
5 or more countries • 33%
0 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
More than 10 countries • 25%
0-5 • 25%
6-10 • 25%
11-20 • 25%
21+ • 25%